Key result
Maternal aspirin exposure in utero was associated with a lower frequency of hs-PDA and earlier PDA closure (day 4 vs 11, p=0.02) compared to no exposure in preterm infants.
Why the study?
To assess the burden of hemodynamically significant patent ductus arteriosus in preterm infants exposed to aspirin in utero.
Does maternal aspirin treatment during gestation reduce the incidence of hemodynamically significant patent ductus arteriosus in preterm infants?
Cohort (n=63)
Does maternal aspirin treatment during gestation reduce the incidence of hemodynamically significant patent ductus arteriosus in preterm infants?
Maternal aspirin treatment during pregnancy may reduce the incidence of hemodynamically significant patent ductus arteriosus and improve responsiveness to postnatal ibuprofen in preterm infants.
Maternal aspirin exposure was associated with earlier hs-PDA closure in preterm infants; hypothesis-generating and requires prospective validation before clinical adoption.
Aim: To assess the burden of hemodynamically significant patent ductus arteriosus (hs-PDA) in preterm infants exposed to aspirin in utero.Methods: We retrospectively reviewed the medical records of 21 preterm infants <34 weeks whose mothers were treated with aspirin during gestation, and were screened for patent ductus arteriosus due to severe respiratory distress syndrome and the need for positive pressure ventilation. These infants were compared to 42 preterm infants born without exposure to aspirin in utero.Results: We found significantly lower frequency of hs-PDA and higher rate of successful pharmacological PDA closure after single course of ibuprofen treatment along with significantly lower cumulative doses of ibuprofen in the study group. Furthermore, PDA closure was achieved significantly earlier in the study group (day 4 versus 11, p = .02).Conclusion: Aspirin treatment during pregnancy seemed to reduce the incidence of hs-PDA in preterm infant and to increase infant responsiveness to postnatal medical treatment of PDA.
No takes yet. Share an insight, caveat, or question.
Fridman et al. (2020) conducted a cohort in Hemodynamically significant patent ductus arteriosus in preterm infants (n=63). Maternal aspirin treatment in utero vs. No exposure to aspirin in utero was evaluated on Frequency of hemodynamically significant patent ductus arteriosus (hs-PDA) and time to PDA closure (p=0.02). Maternal aspirin exposure in utero was associated with a lower frequency of hs-PDA and earlier PDA closure (day 4 vs 11, p=0.02) compared to no exposure in preterm infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: